Sana Biotechnology, Inc. — Form 10-Q Summary
Reporting period: Quarter ended September 30, 2023; filed November 8, 2023. Amounts below are in U.S. dollars. Sana is a development-stage biotechnology company developing engineered-cell therapies and had no approved products or product-sales revenue.
Key financial metrics
| Metric | Q3 2023 | Q3 2022 | Nine months 2023 | Nine months 2022 |
|---|---|---|---|---|
| Revenue | No product revenue | No product revenue | No product revenue | No product revenue |
| Research and development expense | $65.6 million | $76.7 million | $205.8 million | $222.0 million |
| General and administrative expense | $19.2 million | $15.5 million | $52.5 million | $48.2 million |
| Net income (loss) | $1.0 million | $(85.1) million | $(195.1) million | $(189.0) million |
| Cash used in operating activities | Not separately presented for the quarter | $(201.6) million | $(214.0) million |
Q3 2023 operating expenses were $2.2 million and operating loss was $2.2 million, chiefly because of an $82.6 million non-cash gain from revaluing success-payment and contingent-consideration liabilities. This accounting gain—not product revenue—drove the reported quarterly net income. Excluding that gain, reported operating expenses would have been approximately $84.8 million.
At September 30, 2023, cash and cash equivalents were $168.4 million and marketable securities were $100.1 million, totaling $268.6 million of cash, cash equivalents, and marketable securities. Current assets were $279.5 million against current liabilities of $66.6 million. The company reported no debt outstanding. It had $96.9 million of operating lease liabilities and $103.2 million of contingent consideration liabilities, plus $12.4 million of success-payment liabilities.
Changes versus comparable periods
- Q3 net results improved by $86.1 million year over year, primarily reflecting much larger fair-value gains on acquisition-related liabilities; Sana still incurred substantial underlying research and development and administrative costs.
- For the first nine months, net loss widened by $6.1 million year over year, although operating cash use declined by $12.4 million.
- Nine-month R&D expense fell $16.1 million, mainly from lower laboratory, third-party manufacturing, and technology-licensing costs; G&A rose $4.3 million.
- Cash, cash equivalents, and marketable securities declined from $434.0 million at December 31, 2022 to $268.6 million at September 30, 2023. The company raised $27.6 million net through its at-the-market facility by period-end.
Outlook, commentary, and risks
- Management said September 30 liquidity was expected to fund working capital and capital expenditures for at least 12 months from the financial-statement filing date. Sana expects to need additional financing in the future; it cautioned that financing may not be available on acceptable terms.
- In October 2023, after quarter-end, Sana announced a strategic repositioning to prioritize ex vivo cell-therapy candidates and reduce near-term investment in its in vivo fusogen platform, including delaying the SG299 IND submission. The change included a workforce reduction of approximately 29%; the company expected about $6.8 million of cash severance and related costs, with actions substantially complete by Q1 2024.
- Management expected 2024 operating cash burn to be below $200 million and operating losses and expenses to decline in 2024, excluding one-time items. Longer-term expenses could rise if clinical programs advance or R&D expands.
- Clinical and regulatory plans remain uncertain. The filing described ongoing Phase 1 development of SC291 and planned or potential studies and data readouts, but those plans are forward-looking and subject to trial, regulatory, manufacturing, and funding risks.
- Major disclosed risks include unproven cell-engineering technologies, clinical safety and efficacy uncertainty, complex manufacturing and dependence on CDMOs, supply-chain constraints, intellectual-property and licensing exposure, and the need for additional capital. Fair-value estimates for contingent consideration and success payments are sensitive to assumptions and can materially move GAAP results.
- The Fremont facility lease was terminated in August 2023, producing a $2.7 million loss included in G&A. The planned manufacturing facility is in Bothell, Washington; the filing said it could take several years before it is able to manufacture product candidates there.
Most important facts for investors to verify
- Whether the October 2023 portfolio shift, workforce reduction, and projected sub-$200 million 2024 operating cash burn are delivered as planned.
- Actual clinical progress and data for SC291 and other prioritized programs, including any changes to anticipated IND submissions and readout timing.
- Cash runway under updated operating plans, future financing needs, and any dilution from equity issuance or the remaining ATM capacity.
- Whether the large non-cash fair-value gains recur or reverse; they are not operating cash inflows and materially affect reported earnings.
- Progress, cost, and timing of Bothell manufacturing capabilities and continued reliance on third-party manufacturers.